Teniposide (BioDeep_00000008520)

 

Secondary id: BioDeep_00001873794

human metabolite blood metabolite


代谢物信息卡片


(10R,11R,15R,16S)-16-{[(4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1,3(7),8-trien-12-one

化学式: C32H32O13S (656.1563542)
中文名称: 替尼泊苷
谱图信息: 最多检出来源 Homo sapiens(blood) 90.63%

分子结构信息

SMILES: COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C7C(O6)COC(O7)C8=CC=CS8)O)O
InChI: InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1

描述信息

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. [PubChem]
Same as: D02698

同义名列表

22 个代谢物同义名

(10R,11R,15R,16S)-16-{[(4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1,3(7),8-trien-12-one; 4-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside); 4-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-b-D-glucopyranoside); 4-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-β-D-glucopyranoside); 4-Demethylepipodophyllotoxin-beta-D-thenylidene glucoside; 4-Demethylepipodophyllotoxin-b-D-thenylidene glucoside; 4-Demethylepipodophyllotoxin-β-D-thenylidene glucoside; Demethyl epipodophyllotoxin thenylidine glucoside; Teniposide, (5a alpha,9 alpha(s*))-isomer; Bristol myers squibb brand OF teniposide; Bristol-myers squibb brand OF teniposide; Bristol myers brand OF teniposide; Bristol-myers brand OF teniposide; Teniposidum; NSC 122819; Teniposido; teniposide; NSC-122819; HSDB 6546; VM 26; Vumon; VM-26



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

2 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(2)

PharmGKB(0)

2 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Susan Bal, Heather Landau. AL amyloidosis: untangling new therapies. Hematology. American Society of Hematology. Education Program. 2021 12; 2021(1):682-688. doi: 10.1182/hematology.2021000305. [PMID: 34889374]
  • Hadas Rabani, Mira Ziv, Noa Lavi, Ariel Aviv, Celia Suriu, Adel Shalata, Yarin Haddid, Tamar Tadmor. Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma. Leukemia research. 2020 12; 99(?):106476. doi: 10.1016/j.leukres.2020.106476. [PMID: 33171301]
  • Shahin Ahmadian, Sepideh Sheshpari, Mahdi Mahdipour, Mohammad Pazhang, Pei-Shiue Jason Tsai, Mohammad Nouri, Reza Rahbarghazi, Mahnaz Shahnazi. Toxic effects of VCD on kidneys and liver tissues: a histopathological and biochemical study. BMC research notes. 2019 Jul; 12(1):446. doi: 10.1186/s13104-019-4490-y. [PMID: 31331386]
  • Lipei Liu, Peng Zeng, Xiaoxiao Yang, Yajun Duan, Wenwen Zhang, Chuanrui Ma, Xiaomeng Zhang, Shu Yang, Xiaoju Li, Jie Yang, Yu Liang, Hao Han, Yan Zhu, Jihong Han, Yuanli Chen. Inhibition of Vascular Calcification. Arteriosclerosis, thrombosis, and vascular biology. 2018 10; 38(10):2382-2395. doi: 10.1161/atvbaha.118.311546. [PMID: 30354214]
  • Pedro Russo, Ana Luisa Tomé, Tiago Capela, Maria João Bettencourt. Anorectal involvement in a patient with multiple myeloma. BMJ case reports. 2017 Apr; 2017(?):. doi: 10.1136/bcr-2017-219658. [PMID: 28420651]
  • Bingyang Chu, Shuai Shi, Xingyi Li, Lufeng Hu, Lu Shi, Haina Zhang, Qiaoqiao Xu, Lei Ye, Guanyang Lin, Nansheng Zhang, Xiuhua Zhang. Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy. International journal of pharmaceutics. 2016 Nov; 513(1-2):118-129. doi: 10.1016/j.ijpharm.2016.09.005. [PMID: 27596115]
  • Xinyi He, Nanxi Xiang, Jinjie Zhang, Jing Zhou, Yao Fu, Tao Gong, Zhirong Zhang. Encapsulation of teniposide into albumin nanoparticles with greatly lowered toxicity and enhanced antitumor activity. International journal of pharmaceutics. 2015 Jun; 487(1-2):250-9. doi: 10.1016/j.ijpharm.2015.04.047. [PMID: 25899285]
  • Mengyang Liu, Yuanli Chen, Ling Zhang, Qixue Wang, Xingzhe Ma, Xiaoju Li, Rong Xiang, Yan Zhu, Shucun Qin, Yang Yu, Xian-cheng Jiang, Yajun Duan, Jihong Han. Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. The Journal of biological chemistry. 2015 Jun; 290(23):14418-29. doi: 10.1074/jbc.m115.643015. [PMID: 25914138]
  • Thi Thanh Hanh Nguyen, Seung-Jin Jung, Hee-Kyoung Kang, Young-Min Kim, Young-Hwan Moon, Misook Kim, Doman Kim. Production of rubusoside from stevioside by using a thermostable lactase from Thermus thermophilus and solubility enhancement of liquiritin and teniposide. Enzyme and microbial technology. 2014 Oct; 64-65(?):38-43. doi: 10.1016/j.enzmictec.2014.07.001. [PMID: 25152415]
  • Liliane Hobeika, Sally E Self, Juan Carlos Q Velez. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC nephrology. 2014 Sep; 15(?):156. doi: 10.1186/1471-2369-15-156. [PMID: 25267524]
  • Ayato Tsukamoto, Yumiko Yoshiki, Sho Yamazaki, Keiki Kumano, Fumihiko Nakamura, Mineo Kurokawa. The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion. Annals of hematology. 2014 Mar; 93(3):507-8. doi: 10.1007/s00277-013-1818-x. [PMID: 23797638]
  • Zhiwen Zhang, Zeying Liu, Li Ma, Shijun Jiang, Yixin Wang, Haijun Yu, Qi Yin, Jingbin Cui, Yaping Li. Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine. Molecular pharmaceutics. 2013 Jun; 10(6):2426-34. doi: 10.1021/mp400039j. [PMID: 23679827]
  • Ling Zhang, Meixiu Jiang, Yongsheng Shui, Yuanli Chen, Qixue Wang, Wenquan Hu, Xingzhe Ma, Xiaoju Li, Xin Liu, Xingyue Cao, Mengyang Liu, Yajun Duan, Jihong Han. DNA topoisomerase II inhibitors induce macrophage ABCA1 expression and cholesterol efflux-an LXR-dependent mechanism. Biochimica et biophysica acta. 2013 Jun; 1831(6):1134-45. doi: 10.1016/j.bbalip.2013.02.007. [PMID: 23466610]
  • Suna He, Zheng Cui, Dong Mei, Hua Zhang, Xueqing Wang, Wenbing Dai, Qiang Zhang. A cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo. AAPS PharmSciTech. 2012 Sep; 13(3):846-52. doi: 10.1208/s12249-012-9809-0. [PMID: 22644709]
  • S A Bakheet, S M Attia, N M Al-Rasheed, M M Al-Harbi, A E Ashour, H M Korashy, A R Abd-Allah, Q Saquib, A A Al-Khedhairy, J Musarrat. Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells. Mutagenesis. 2011 Jul; 26(4):533-43. doi: 10.1093/mutage/ger013. [PMID: 21430063]
  • Jing Wang, Yu Zhang, Tingting Guan, Xia Lin, Xing Tang, Hui Xu. Determination of teniposide in rat plasma by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry after intravenous administration. Biomedical chromatography : BMC. 2009 Sep; 23(9):999-1006. doi: 10.1002/bmc.1214. [PMID: 19382244]
  • Jing Wang, Yue Cui, Xing Tang. Chemical stability of teniposide in aqueous and parenteral lipid emulsions. Drug development and industrial pharmacy. 2009 Apr; 35(4):508-13. doi: 10.1080/03639040802468016. [PMID: 18991092]
  • Wan-tao Chen, Xiao-jian Zhou, Qin Xu, Wei Guo, Han-guang Zhu, Wei-min Ye. [Chemosensitivity testing of oral squamous cell carcinomas with teniposide]. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology. 2003 Nov; 38(6):441-3. doi: NULL. [PMID: 14703479]
  • U Naumann, S Weit, J Wischhusen, M Weller. Diva/Boo is a negative regulator of cell death in human glioma cells. FEBS letters. 2001 Sep; 505(1):23-6. doi: 10.1016/s0014-5793(01)02768-5. [PMID: 11557035]
  • E Solary, L Mannone, D Moreau, D Caillot, R O Casasnovas, H Guy, M Grandjean, J E Wolf, F André, P Fenaux, P Canal, B Chauffert, A Wotawa, M Bayssas, P Genne. Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. Leukemia. 2000 Dec; 14(12):2085-94. doi: 10.1038/sj.leu.2401945. [PMID: 11187897]
  • S Pandey, B Smith, P R Walker, M Sikorska. Caspase-dependent and independent cell death in rat hepatoma 5123tc cells. Apoptosis : an international journal on programmed cell death. 2000 Jun; 5(3):265-75. doi: 10.1023/a:1009608630145. [PMID: 11225848]
  • J Zhou, Q Zhu, H Yao. [Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2000 May; 22(3):225-7. doi: NULL. [PMID: 11778237]
  • G Toffoli, P Aita, R Sorio, G Corona, A Bertola, A M Colussi, I Robieux, M Boiocchi. Effect of cyclosporin A on protein binding of teniposide in cancer patients. Anti-cancer drugs. 1999 Jul; 10(6):511-8. doi: 10.1097/00001813-199907000-00001. [PMID: 10885897]
  • M Kool, M van der Linden, M de Haas, G L Scheffer, J M de Vree, A J Smith, G Jansen, G J Peters, N Ponne, R J Scheper, R P Elferink, F Baas, P Borst. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proceedings of the National Academy of Sciences of the United States of America. 1999 Jun; 96(12):6914-9. doi: 10.1073/pnas.96.12.6914. [PMID: 10359813]
  • A Cheng, Z Peng, Z Hong. [A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer]. Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao. 1999 Mar; 30(1):95-8. doi: NULL. [PMID: 12205938]
  • R S de Jong, N H Mulder, D R Uges, D T Sleijfer, F J Höppener, H J Groen, P H Willemse, W T van der Graaf, E G de Vries. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. British journal of cancer. 1999 Feb; 79(5-6):882-7. doi: 10.1038/sj.bjc.6690141. [PMID: 10070885]
  • A Hueber, S Durka, M Weller. CD95-mediated apoptosis: no variation in cellular sensitivity during cell cycle progression. FEBS letters. 1998 Aug; 432(3):155-7. doi: 10.1016/s0014-5793(98)00855-2. [PMID: 9720915]
  • P Solal-Céligny, E Lepage, N Brousse, C L Tendler, P Brice, C Haïoun, J Gabarre, B Pignon, G Tertian, R Bouabdallah, J F Rossi, C Doyen, B Coiffier. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jul; 16(7):2332-8. doi: 10.1200/jco.1998.16.7.2332. [PMID: 9667247]
  • N Nagai, T Shikii, K Mihara, H Ogata, Y Sasaki. Improved high-performance liquid chromatographic analysis of teniposide in human plasma. Journal of chromatography. B, Biomedical sciences and applications. 1998 May; 709(2):315-9. doi: 10.1016/s0378-4347(98)00059-0. [PMID: 9657231]
  • V T Solov'yan, I O Andreev, T Y Kolotova, P V Pogribniy, D T Tarnavsky, V A Kunakh. The cleavage of nuclear DNA into high molecular weight DNA fragments occurs not only during apoptosis but also accompanies changes in functional activity of the nonapoptotic cells. Experimental cell research. 1997 Aug; 235(1):130-7. doi: 10.1006/excr.1997.3651. [PMID: 9281361]
  • L C Bowman, R P Castleberry, A Cantor, V Joshi, S L Cohn, E I Smith, A Yu, G M Brodeur, F A Hayes, A T Look. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. Journal of the National Cancer Institute. 1997 Mar; 89(5):373-80. doi: 10.1093/jnci/89.5.373. [PMID: 9060959]
  • L Testolin, C Carson, Y Wang, P R Walker, U Armato, M Sikorska. Jun and JNK kinase are activated in thymocytes in response to VM26 and radiation but not glucocorticoids. Experimental cell research. 1997 Feb; 230(2):220-32. doi: 10.1006/excr.1996.3419. [PMID: 9024781]
  • P R Andreassen, F B Lacroix, R L Margolis. Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure. The Journal of cell biology. 1997 Jan; 136(1):29-43. doi: 10.1083/jcb.136.1.29. [PMID: 9008701]
  • G Toffoli, R Sorio, M Gigante, G Corona, E Galligioni, M Boiocchi. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. British journal of cancer. 1997; 75(5):715-21. doi: 10.1038/bjc.1997.127. [PMID: 9043030]
  • O van Tellingen, W Boogerd, W J Nooijen, J H Beijnen. The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer chemotherapy and pharmacology. 1997; 40(4):330-4. doi: 10.1007/s002800050665. [PMID: 9225951]
  • K Son, H Alkan-Onyuksel. Stabilization of teniposide in aqueous mixtures of detergent-phospholipid. PDA journal of pharmaceutical science and technology. 1996 Nov; 50(6):366-71. doi: NULL. [PMID: 9038082]
  • E Liliemark, L Herngren, B Pettersson, C Peterson, J Liliemark. Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide. Cancer letters. 1996 Aug; 106(1):91-6. doi: 10.1016/0304-3835(96)04307-8. [PMID: 8827051]
  • K Son, H Alkan-Onyuksel. Physical stability of teniposide in bile salt-egg phosphatidylcholine mixed micelles and liposomes. PDA journal of pharmaceutical science and technology. 1996 Mar; 50(2):89-93. doi: ". [PMID: 8935776]
  • J H Lin, F J Castora. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Archives of biochemistry and biophysics. 1995 Dec; 324(2):293-9. doi: 10.1006/abbi.1995.0042. [PMID: 8554321]
  • E Liliemark, J Liliemark, N Kållberg, M Björkholm, B Sjöström, C Peterson. Studies of the organ distribution in mice of teniposide liposomes designed for treatment of diseases in the mononuclear phagocytic system. Pediatric research. 1995 Jul; 38(1):7-10. doi: 10.1203/00006450-199507000-00002. [PMID: 7478800]
  • M Gigante, R Sorio, A M Colussi, A Sandrin, L De Appollonia, E Galligioni, A Freschi, R Talamini, G Toffoli, M Boiocchi. Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer. Anti-cancer drugs. 1995 Jun; 6(3):479-82. doi: 10.1097/00001813-199506000-00019. [PMID: 7670149]
  • E Liliemark, B Sjöström, J Liliemark, C Peterson, N Kållberg, B S Larsson. Targeting of teniposide to the mononuclear phagocytic system (MPS) by incorporation in liposomes and submicron lipid particles; an autoradiographic study in mice. Leukemia & lymphoma. 1995 Jun; 18(1-2):113-8. doi: 10.3109/10428199509064930. [PMID: 8580812]
  • P Kubisz, F Seghier, M Dobrotorá, J Stasko, S Cronberg. Influence of teniposide on platelet functions in vitro. Thrombosis research. 1995 Jan; 77(2):145-8. doi: 10.1016/0049-3848(95)91620-z. [PMID: 7740506]
  • V T Solovyan, I O Andreyev. Structural domains of plant nuclear DNA as a constitutive component of the topoisomerase II/DNA complex. Acta biochimica Polonica. 1995; 42(2):201-4. doi: 10.18388/abp.1995_4609. [PMID: 8588464]
  • P A Permana, R M Snapka, L L Shen, D T Chu, J J Clement, J J Plattner. Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry. 1994 Sep; 33(37):11333-9. doi: 10.1021/bi00203a031. [PMID: 7727384]
  • S P Joel, M L Slevin. Schedule-dependent topoisomerase II-inhibiting drugs. Cancer chemotherapy and pharmacology. 1994; 34 Suppl(?):S84-8. doi: 10.1007/bf00684869. [PMID: 8070033]
  • M V Relling, R K Mulhern, D Fairclough, D Baker, C H Pui. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. The Journal of pediatrics. 1993 Nov; 123(5):811-6. doi: 10.1016/s0022-3476(05)80866-2. [PMID: 8229497]
  • D Z D'Argenio, J H Rodman. Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective. Journal of pharmacokinetics and biopharmaceutics. 1993 Apr; 21(2):223-51. doi: 10.1007/bf01059772. [PMID: 8229682]
  • M L Espinás, M Carballo. Pulsed-field gel electrophoresis analysis of higher-order chromatin structures of Zea mays. Highly methylated DNA in the 50 kb chromatin structure. Plant molecular biology. 1993 Mar; 21(5):847-57. doi: 10.1007/bf00027116. [PMID: 8385508]
  • J H Rodman, W L Furman, M Sunderland, G Rivera, W E Evans. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Feb; 11(2):287-93. doi: 10.1200/jco.1993.11.2.287. [PMID: 8426206]
  • D J Stewart, D Grewaal, M D Redmond, N Z Mikhael, V A Montpetit, R Goel, R M Green. Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. Cancer chemotherapy and pharmacology. 1993; 32(5):368-72. doi: 10.1007/bf00735921. [PMID: 8339387]
  • H Alkan-Onyuksel, K Son. Mixed micelles as proliposomes for the solubilization of teniposide. Pharmaceutical research. 1992 Dec; 9(12):1556-62. doi: 10.1023/a:1015804206414. [PMID: 1488398]
  • E Friche, M K Danks, W T Beck. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo. Cancer research. 1992 Oct; 52(20):5701-6. doi: . [PMID: 1356619]
  • G Rappa, A Lorico, A C Sartorelli. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). International journal of cancer. 1992 Jul; 51(5):780-7. doi: 10.1002/ijc.2910510519. [PMID: 1377186]
  • M Boiocchi, L Tumiotto, F Giannini, A Viel, G Biscontin, F Sartor, G Toffoli. P-glycoprotein but not topoisomerase II and glutathione-S-transferase-pi accounts for enhanced intracellular drug-resistance in LoVo MDR human cell lines. Tumori. 1992 Jun; 78(3):159-66. doi: 10.1177/030089169207800303. [PMID: 1359686]
  • P I Clark. Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Seminars in oncology. 1992 Apr; 19(2 Suppl 6):20-7. doi: NULL. [PMID: 1411635]
  • T A Splinter, J J Holthuis, T C Kok, M H Post. Absolute bioavailability and pharmacokinetics of oral teniposide. Seminars in oncology. 1992 Apr; 19(2 Suppl 6):28-34. doi: NULL. [PMID: 1411636]
  • P R Andreassen, R L Margolis. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proceedings of the National Academy of Sciences of the United States of America. 1992 Mar; 89(6):2272-6. doi: 10.1073/pnas.89.6.2272. [PMID: 1549593]
  • D K Baker, M V Relling, C H Pui, M L Christensen, W E Evans, J H Rodman. Increased teniposide clearance with concomitant anticonvulsant therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1992 Feb; 10(2):311-5. doi: 10.1200/jco.1992.10.2.311. [PMID: 1732431]
  • W P Petros, J H Rodman, M V Relling, M Christensen, C H Pui, G K Rivera, W E Evans. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations. Pharmacotherapy. 1992; 12(4):273-7. doi: . [PMID: 1518726]
  • W E Evans, J H Rodman, M V Relling, W P Petros, C F Stewart, C H Pui, G K Rivera. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. The Journal of pharmacology and experimental therapeutics. 1992 Jan; 260(1):71-7. doi: NULL. [PMID: 1731053]
  • W K Nishioka, R M Welsh. Inhibition of cytotoxic T lymphocyte-induced target cell DNA fragmentation, but not lysis, by inhibitors of DNA topoisomerases I and II. The Journal of experimental medicine. 1992 Jan; 175(1):23-7. doi: 10.1084/jem.175.1.23. [PMID: 1309853]
  • F Manso, J L Bello, J Feliu, J García de Bustos, G Losada, E Quevedo. [Plasma cell leukemia: our experience in 4 cases]. Revista clinica espanola. 1991 Nov; 189(7):328-30. doi: NULL. [PMID: 1767090]
  • F A van der Horst, M A van Opstal, J Teeuwsen, M H Post, J J Holthuis, U A Brinkman. Comparative study on the determination of the anti-neoplastic drug teniposide in plasma using micellar liquid chromatography and surfactant-mediated plasma clean-up. Journal of chromatography. 1991 Jun; 567(1):161-74. doi: 10.1016/0378-4347(91)80320-c. [PMID: 1918243]
  • E Chatelut, M de Forni, P Canal, C Chevreau, H Roche, Y Plusquellec, N P Johnson, G Houin, R Bugat. Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Annals of oncology : official journal of the European Society for Medical Oncology. 1991 Mar; 2(3):217-21. doi: 10.1093/oxfordjournals.annonc.a057910. [PMID: 2043492]
  • M Carballo, R Giné, M Santos, P Puigdomènech. Characterization of topoisomerase I and II activities in nuclear extracts during callogenesis in immature embryos of Zea mays. Plant molecular biology. 1991 Jan; 16(1):59-70. doi: 10.1007/bf00017917. [PMID: 1653630]
  • H L McLeod, D K Baker, C H Pui, J H Rodman. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. Cancer chemotherapy and pharmacology. 1991; 29(2):150-4. doi: 10.1007/bf00687326. [PMID: 1760858]
  • P Ujházy, O Babusíková. NK-cell activity affected by some cytostatic drugs and their additives. Neoplasma. 1991; 38(3):303-12. doi: NULL. [PMID: 1857450]
  • W P Petros, J H Rodman, J Mirro, W E Evans. Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer chemotherapy and pharmacology. 1991; 27(5):397-400. doi: 10.1007/bf00688865. [PMID: 1999001]
  • J Ochs, J Rodman, M Abromowitch, R Kavanagh, M Harris, J Yalowich, G K Rivera. A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Jan; 9(1):139-44. doi: 10.1200/jco.1991.9.1.139. [PMID: 1985163]
  • M Zucchetti, C Rossi, R Knerich, M G Donelli, G Butti, V Silvani, P Gaetani, M D'Incalci. Concentrations of VP16 and VM26 in human brain tumors. Annals of oncology : official journal of the European Society for Medical Oncology. 1991 Jan; 2(1):63-6. doi: 10.1093/oxfordjournals.annonc.a057826. [PMID: 2009235]
  • J H Rodman, M Sunderland, R L Kavanagh, J Ochs, J Yalowich, W E Evans, G K Rivera. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Cancer research. 1990 Jul; 50(14):4267-71. doi: NULL. [PMID: 2194652]
  • M Reitman, G Felsenfeld. Developmental regulation of topoisomerase II sites and DNase I-hypersensitive sites in the chicken beta-globin locus. Molecular and cellular biology. 1990 Jun; 10(6):2774-86. doi: 10.1128/mcb.10.6.2774-2786.1990. [PMID: 2160585]
  • S E Wright, J C White, L Huang. Partitioning of teniposide into membranes and the role of lipid composition. Biochimica et biophysica acta. 1990 Jan; 1021(2):105-13. doi: 10.1016/0005-2736(90)90021-f. [PMID: 2302390]
  • S E Wright, L H Hines, J C White. Effects of the lipophilic anticancer drug teniposide (VM-26) on membrane transport. Chemico-biological interactions. 1990; 75(1):31-48. doi: 10.1016/0009-2797(90)90020-n. [PMID: 2364457]
  • M A van Opstal, F A van der Horst, J J Holthuis, W P van Bennekom, A Bult. Automated reversed-phase chromatographic analysis of etoposide and teniposide in plasma by using on-line surfactant-mediated sample clean-up and column-switching. Journal of chromatography. 1989 Oct; 495(?):139-51. doi: 10.1016/s0378-4347(00)82617-1. [PMID: 2613799]
  • P Canal, Y Plusquellec, E Chatelut, R Bugat, J De Biasi, G Houin. A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humans. Journal of pharmaceutical sciences. 1989 May; 78(5):389-92. doi: 10.1002/jps.2600780509. [PMID: 2746477]
  • P Canal, R Bugat, E Chatelut, M C Pinel, G Houin, Y Plusquellec, M Carton. Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26). European journal of cancer & clinical oncology. 1989 May; 25(5):815-20. doi: 10.1016/0277-5379(89)90126-0. [PMID: 2737218]
  • F Ben-Ayed, M Halphen, T Najjar, H Boussene, H Jaafoura, A Bouguerra, N Ben Salah, N Mourali, K Ayed, H Ben Khalifa. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer. 1989 Apr; 63(7):1251-6. doi: 10.1002/1097-0142(19890401)63:7<1251::aid-cncr2820630704>3.0.co;2-h. [PMID: 2920354]
  • N Winick, G R Buchanan, S B Murphy, A Yu, J Boyett. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study. Medical and pediatric oncology. 1988; 16(5):327-32. doi: 10.1002/mpo.2950160507. [PMID: 3263563]
  • N Oishi, J Berenberg, B A Blumenstein, K Johnson, S E Rivkin, R M Bukowski, R M O'Bryan, R L Stephens, J Quagliana, J H Saiers. Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study. Cancer treatment reports. 1987 Dec; 71(12):1307-8. doi: NULL. [PMID: 3690547]
  • W T Beck, M C Cirtain, M K Danks, R L Felsted, A R Safa, J S Wolverton, D P Suttle, J M Trent. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer research. 1987 Oct; 47(20):5455-60. doi: . [PMID: 2888532]
  • J H Rodman, M Abromowitch, J A Sinkule, F A Hayes, G K Rivera, W E Evans. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987 Jul; 5(7):1007-14. doi: 10.1200/jco.1987.5.7.1007. [PMID: 3598607]
  • J J Holthuis, L G de Vries, P E Postmus, W W van Oort, H Verleun, A Hulshoff, D T Sleijfer, N H Mulder. Pharmacokinetics of high-dose teniposide. Cancer treatment reports. 1987 Jun; 71(6):599-603. doi: NULL. [PMID: 3581097]
  • P I Clark, M L Slevin. The clinical pharmacology of etoposide and teniposide. Clinical pharmacokinetics. 1987 Apr; 12(4):223-52. doi: 10.2165/00003088-198712040-00001. [PMID: 3297462]
  • D Roberts, T Lee, E Parganas, L Wiggins, J Yalowich, R Ashmun. Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells. Cancer chemotherapy and pharmacology. 1987; 19(2):123-30. doi: 10.1007/bf00254563. [PMID: 3568269]
  • F Figoli, M L Zanette, U Tirelli, R Sorio, C Lestuzzi, R Urso, S Monfardini, M D'Incalci. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer chemotherapy and pharmacology. 1987; 20(3):239-42. doi: 10.1007/bf00570493. [PMID: 2824081]
  • S E Wright, J C White. Membrane ordering effects of the anticancer agent VM-26. Biochimica et biophysica acta. 1986 Dec; 863(2):297-304. doi: 10.1016/0005-2736(86)90270-1. [PMID: 3024721]
  • Y Matsushima, F Kanzawa, N Miyazawa, Y Sasaki, N Saijo. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. Anticancer research. 1986 Sep; 6(5):921-4. doi: NULL. [PMID: 3026235]
  • E Osby, M Beksac, P Reizenstein. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Anticancer research. 1986 Sep; 6(5):1145-7. doi: NULL. [PMID: 3800322]
  • S E Wright, J C White. Teniposide-induced changes in the physical properties of phosphatidylcholine liposomes. A calorimetric study. Biochemical pharmacology. 1986 Aug; 35(16):2731-5. doi: 10.1016/0006-2952(86)90182-6. [PMID: 3741467]
  • P Canal, C Michel, R Bugat, G Soula, M Carton. Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1986 Mar; 375(2):451-6. doi: 10.1016/s0378-4347(00)83742-1. [PMID: 3700571]
  • T Colombo, M Broggini, M Vaghi, G Amato, E Erba, M D'Incalci. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. European journal of cancer & clinical oncology. 1986 Feb; 22(2):173-9. doi: 10.1016/0277-5379(86)90027-1. [PMID: 3699080]
  • D H Ho, K S Kanellopoulos, N S Brown, B F Issell, G P Bodey. Radioimmunoassay for etoposide and teniposide. Journal of immunological methods. 1985 Dec; 85(1):5-15. doi: 10.1016/0022-1759(85)90269-8. [PMID: 4078312]
  • D A Gewirtz. Serum protein reduction of the enhancement of methotrexate accumulation by vincristine and 4'-demethylepipodophyllotoxin in the Ehrlich ascites tumor cell in vitro. Cancer research. 1985 Dec; 45(12 Pt 1):6290-2. doi: . [PMID: 4063980]
  • D C Doll, R B Weiss. Hemolytic anemia associated with antineoplastic agents. Cancer treatment reports. 1985 Jul; 69(7-8):777-82. doi: NULL. [PMID: 3160460]
  • M D'Incalci, C Rossi, C Sessa, R Urso, M Zucchetti, P Farina, C Mangioni. Pharmacokinetics of teniposide in patients with ovarian cancer. Cancer treatment reports. 1985 Jan; 69(1):73-7. doi: NULL. [PMID: 3967261]
  • P Canal, R Bugat, C Michel, H Roche, G Soula, P F Combes. Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma. Cancer chemotherapy and pharmacology. 1985; 15(2):149-52. doi: 10.1007/bf00257526. [PMID: 4017164]
  • J R Raymond. Nephrotoxicities of antineoplastic and immunosuppressive agents. Current problems in cancer. 1984 Oct; 8(16):1-32. doi: 10.1016/s0147-0272(84)80013-6. [PMID: 6238806]